Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | CASP6 | P55212 | 1/20 | 0.72 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.67 |
| ▸ | CDC42 | P60953 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.50 |
| ▸ | RB1 | P06400 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4158259 | 0.99 | GAA (0.74) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5460613 | 0.97 | GAA (0.68) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5467984 | 0.93 | GAA (0.62) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL28488725 | 0.93 | GAA (0.69) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5455548 | 0.89 | PRMT5 (0.72) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5461938 | 0.89 | GAA (0.70) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5459664 | 0.89 | GAA (0.70) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5456604 | 0.89 | GAA (0.69) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL5448104 | 0.88 | GAA (0.65) | GAACASP6PRMT5CDC42SIRT1 | |
| SCHEMBL4196072 | 0.87 | CYP2D6 (0.67) | GAACASP6PRMT5CDC42CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1678137-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037791-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | GAA 1417/4885CASP6 3264/4885PRMT5 1060/4885 |
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | GAA 908/4885CASP6 2539/4885PRMT5 3261/4885 |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RNMT, RRM2B | GAA 1007/4885CASP6 2464/4885PRMT5 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.